LSN tracks investor behavior within the life sciences on a global basis, and in recent times, an interesting trend has emerged in terms of capital dynamics between the US and the EU. Though early stage life science companies globally have fallen victim to the consolidation of venture capital, Europe has been particularly troubled. I wrote last month about an accelerating trend of investment dollars flowing into EU life science companies, but my theories were confirmed over the course of this week.
Image Courtesy of tungphoto / FreeDigitalPhotos.net
To read the original article: Validating the New Investment Dynamic Between the US and Europe – Life Science Nation
